Acute respiratory distress syndrome (ARDS) accounts for approximately 10% of all ICU admissions and 23% of patients requiring mechanical ventilation (MV). Despite advances in care, hospital mortality remains high, ranging from 34% in mild cases to 46% in severe ARDS. Positive-pressure MV remains the cornerstone of ARDS management. However, when excessive stress and strain are applied to the lung parenchyma, it can exacerbate lung injury, leading to ventilator-induced lung injury (VILI). VILI substantially contributes to morbidity and mortality in ARDS. Strategies that reduce tidal volume (Vt), driving pressure (ΔP, defined as plateau pressure minus PEEP), and respiratory rate (RR) can lower the mechanical power (PowerRS), i.e., the energy delivered to the lungs by the ventilator. This reduction in pulmonary stress and strain may lessen VILI and potentially improve survival. Nonetheless, reducing Vt to \<6 ml/kg in order to achieve plateau pressures \<23-25 cm H₂O, driving pressures \<9-11 cm H₂O, and RR \<15-20/min can result in severe hypercapnia. This, in turn, may increase intracranial pressure, promote pulmonary hypertension, impair myocardial contractility, reduce renal perfusion, and trigger endogenous catecholamine release. Thus, such "ultraprotective" MV strategies are not feasible for most ARDS patients managed with conventional ventilation. The neutral findings of the REST trial further suggested that low-flow extracorporeal CO₂ removal (ECCO₂R) devices may provide insufficient CO₂ clearance to enable ultraprotective ventilation while adequately controlling respiratory acidosis. Moreover, since partial lung derecruitment may occur with substantial Vt reduction, extracorporeal membrane oxygenation (ECMO) may be necessary, particularly in patients with PaO₂/FiO₂ \<120-130 at the time of Vt reduction. Therefore, respiratory extracorporeal life support (ECLS)-ranging from high-flow ECCO₂R to mid-flow venovenous ECMO (VV-ECMO)-can be employed in this setting. These modalities facilitate further reductions in ventilatory intensity while ensuring adequate oxygenation and CO₂ removal.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
290
* ECLS catheters inserted, and EC LS initiated no later than 12h after randomization * Vt decreased to a min of 3 ml/kg PBW (by 0.5ml/kg every 30 min) to reach ΔP 9 -11 cmH2O and at least 5 cm H2O ΔP decrease * PEEP adjusted to keep the same mean airway pressure * Pump outflow set at 2-4 L/min , based on the need of blood oxygenation * RR decreased to a min of 12/min with gas flowrate adjusted to maintain PaCO2 45 mmHg. * Protocolized weaning of ECLS
Hierarchical criterion assessed at day 30, including all-cause mortality followed by the number of days free from MV at day 30, and calculated in such a manner that death constitutes a worse outcome than duration of ventilation.
Each patient is compared with every other patient in the study and assigned a score (tie: 0, win: +1, loss: -1) for each pairwise comparison based on whom fared better. \- If one patient survived at day 30 and the other did not, scores of +1 and -1 will be assigned, respectively, for that pairwise comparison. If both patients in the pairwise comparison survived at day 30, the assigned score will depend on which patient had more days free from MV at day 30: the patient with more days off MV will receive a score of +1, while the patient with fewer days will receive a score of -1. If both patients survived and had the same number of days off MV, or if both patients died, they will be both assigned a score of 0 for that pairwise comparison. For each patient, scores for all pairwise comparisons will be summed, resulting in a cumulative score.
Time frame: Day 30
Mortality
Time frame: Day 30, Day 60, Day 90
Duration of mechanical ventilation
Time frame: From inclusion to Day 30, from inclusion to Day 60
Number of mechanical ventilation free days
Time frame: Day 30, Day 60
Duration of catecholamine hemodynamic support
Time frame: From inclusion to Day 30, from inclusion to Day 60
Number of catecholamine hemodynamic support free days
Time frame: Day 30, Day 60
Number of organ failure(s) free days
Time frame: Day 30, Day 60
Number of renal replacement therapy free days
Time frame: Day 30, Day 60
Durations of ICU stay
Time frame: Day 90
Duration of hospitalization
Time frame: Day 90
Proportion of patients with Pneumothorax
Time frame: Day 30, Day 60
Proportion of patient with rescue procedures and therapies for severe ARDS
Time frame: Day 90
Incidence of pump malfunction related to ECLS
Time frame: Day 90
Incidence of clotting related to ECLS
Time frame: Day 90
Incidence of air embolism related to ECLS
Time frame: Day 90
Incidence of hemolysis related to ECLS
Time frame: Day 90
Incidence of vein perforation related to ECLS
Time frame: Day 90
Incidence of significant bleeding (related to cannula insertion, at canula site) related to ECLS
Time frame: Day 90
Incidence of major hemorrhage related to ECLS
Time frame: Day 90
Incidence of infection at cannula site related to ECLS
Time frame: Day 90
Incidence of thromboembolic events related to ECLS
Time frame: Day 90
Incidence of stroke related to ECLS
Time frame: Day 90
Incidence of thrombocytopenia related to ECLS
Time frame: Day 90
Incidence of hypofibrinogenemia related to ECLS
Time frame: Day 90
Number of packed red blood cells transfused
Time frame: Day 90
Incidence of ventilator-associated pneumonia
Time frame: From inclusion to Day 30, form inclusion to Day 60
Number of days without organ failure(s), defined with the SOFA score
Time frame: Day 30, Day 60
Number of days without renal replacement therapy
Time frame: Day 30, Day 60
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.